Director, Portfolio Management & Market Research

About Summit:

Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational

bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.

Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:

• HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).

• HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

Overview of Role:

The Director, Portfolio Strategy & Market Research position reports to the Executive Director, Portfolio Strategy to support strategic planning activities by providing actionable recommendations based on assessments of markets and competitors, both existing and potential.

Role and Responsibilities:

• Deliver strategic market and competitive intelligence insights, scenario planning and impact assessment based on in-depth research through presentations and reports to the Executive Director of Portfolio Strategy and various internal management teams to allow effective strategic and tactical decision-making and implementation,
• Conduct in-depth research and analysis on market participants’ products and positioning
• Supply the market and competitive intelligence component of strategic planning and proactively makes recommendations to Executive Director of Portfolio Strategy concerning key intelligence items that require further consideration. Responsible for understanding real-time changes to the competitive and market landscape and communicating the impacts of these changes to the organization
• Partner with internal business stakeholders to enhance their use of strategic analysis, market insights, and competitor intelligence
• Maintain a strong working knowledge of which factors, data points, and other inputs meaningfully impact commercial results in solid tumor oncology markets
• Contribute to development of product revenue for early forecasting modelling of new indications through 18 months prior to a potential commercial product launch